Yarrow Resort Hotel Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2003



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

New Advances in Drug Discovery (A3)


Organizer(s) James A. Wells and Robert F.G. Booth
January 7—12, 2003
Yarrow Resort Hotel • Park City, Utah USA
Abstract Deadline: Sep 16, 2002
Late Abstract Deadline:
Scholarship Deadline:
Early Registration Deadline: Nov 7, 2002

Sponsored by ICOS Corporation

Summary of Meeting:
The Keystone Meeting on New Advances in Drug Discovery is held every other year and is intended to capture the most exciting developments in Industry and Academia related to Drug Discovery. The meeting has traditionally been one of the most dynamic Keystone conferences because of the cross-section of scientists that are assembled to discuss key advances in biopharmaceutical sciences. There are now many opportunities to enhance drug discovery through the utilization of data from the Human Genome Project and through new tools designed to exploit the information. In addition, a variety of novel technologies are emerging which promise to enhance the productivity of drug discovery. All of this is fueled by the need to improve the efficiency of drug discovery. It is the objective of this meeting to focus on the most exciting new technologies, trends and potential success stories in novel areas of drug discovery. Rather than providing broad reviews of general fields or company overviews, the meeting is intended to provide new scientific achievements in the area of biomedical and pharmaceutical research. The meeting will include new breakthroughs in the following areas: New approaches to the discovery of small molecules The impact of genomics and proteomics to drug discovery Emerging target classes New drug candidates In the first part of the meeting the focus will be on the ways in which structural, computational and combinatorial approaches have improved our ability to design small molecules, both in terms of speed and quality. The session on genomics will provide information on the latest advances in these fields and their impact on our understanding of the biology emerging from the human genome project. The ability of these technologies to aid in the identification of attractive new drug targets will be assessed. The majority of small molecule drugs reaching the market have focused on a very limited set of target classes (GPCRs, proteases etc). The third session will focus on newly emerging target classes and the progress that is being made to bring molecules from these classes through to the clinic. The final session will assess the progress that is being made on some of the most exciting targets being focused on within drug discovery. The lessons which can be learned from the hard won experience of this work will be reviewed. In summary, the most exciting current research in emerging fields of drug discovery will be covered during the course of the meeting.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


TUESDAY, JANUARY 7

15:00—19:00
Registration

Lobby
18:15—19:15
Welcome Reception

Summit C
19:15—19:30
Orientation

Summit A-B
19:30—20:30
Keynote Address
Meeting has ended...abstracts no longer viewable online.

Summit A-B
* James A. Wells, University of California, San Francisco, USA

Edward M. Skolnick, ,
Basic Science to Outcomes for Patients


WEDNESDAY, JANUARY 8

07:00—08:00
Breakfast

Ivers/Hearst/Kearns & Mountain View
08:00—11:00
New Approaches to Small Molecule Drug Discovery I
Meeting has ended...abstracts no longer viewable online.

Summit A-B
* James A. Wells, University of California, San Francisco, USA

Wayne A. Hendrickson, Columbia University, USA
Role of Structural Genomics in Drug Discovery

Ruben Abagyan, University of California, San Diego, USA
Docking and Virtual Screening in Lead Drug Discovery

Steven A. Hofstadler, Ibis Therapeutics, USA
Drug Discovery for Structured RNA Targets

Robert McDowell, MyoKardia Inc, USA
Discovering Drugs from Fragments

09:20—09:40
Coffee Break

Summit Hallway
11:00—13:00
Poster Setup

Summit C
13:00—19:30
Poster Session 1 Open Viewing

Summit C
16:15—16:30
Coffee & Snacks Available

Summit Hallway
16:30—18:30
New Approaches to Small Molecule Drug Discovery II
Meeting has ended...abstracts no longer viewable online.

Summit A-B
* Michelle F. Browner, Johnson & Johnson Innovation, USA

Steven V. Ley, University of Cambridge, UK
Parallel Skiing: An Essential Component of Good Parallel Synthesis

Lutz Weber, Morphochem AG, Germany
The Evolution of Combinatorial Libraries

Stephen G. Sligar, University of Illinois at Urbana-Champaign, USA
Short Talk: Self-Assembly of Integral Membrane Proteins into Soluble, Homogeneous Nanometer Scale Phospholipid Bilayer Disk

Michael W. Pantoliano, Millennium Pharmaceuticals, Inc., USA
Short Talk: Drug Discovery Applications of Microfluidics Technology for Kinases

18:30—19:30
Social Hour

Summit C
18:30—19:30
Poster Session 1: New Approaches to Small Molecule Drug Discovery

Summit C

THURSDAY, JANUARY 9

07:00—08:00
Breakfast

Ivers/Hearst/Kearns & Mountain View
08:00—11:00
Impact of Proteomics and Genomics on Drug Discovery I
Meeting has ended...abstracts no longer viewable online.

Summit A-B
* N. Leigh Anderson, Plasma Proteome Institute, USA

John W. Kozarich, ActivX Biosciences, Inc., USA
Activity-Based Proteomics: Enzyme Chemistry Redux

Stephen P.A. Fodor, Cellular Research, Inc., USA
Accessing the Genome

Michael V. Milburn, Metabolon, USA
Scaffold-Based Drug Discovery

Ian McCaffery, Celera Genomics, USA
Target Discovery: The Cell Surface

09:20—09:40
Coffee Break

Summit Hallway
11:00—13:00
Poster Setup

Summit C
13:00—19:30
Poster Session 2 Open Viewing

Summit C
16:15—16:30
Coffee & Snacks Available

Summit Hallway
16:30—18:30
Impact of Proteomics and Genomics on Drug Discovery II
Meeting has ended...abstracts no longer viewable online.

Summit A-B
* Christine M. Debouck, Ardennes Biosciences LLC, USA

David Eisenberg, University of California, Los Angeles, USA
Defining Interacting Partners

Michael P. Snyder, Stanford University School of Medicine, USA
Global Analysis of Protein Activities Using Protein Chips

Mark W. Moore, Deltagen, Inc., USA
From the Genome to Drug Targets via High Throughput Gene Knockouts and Systematic Phenotyping

18:30—19:30
Social Hour

Summit C
18:30—19:30
Poster Session 2: Impact of Proteomics on Drug Discovery

Summit C
21:00—22:00
Panel Discussion: Bottlenecks in Drug Discovery
Meeting has ended...abstracts no longer viewable online.

Summit A-B
* Brian W. Metcalf, Global Blood Therapeutics, USA


FRIDAY, JANUARY 10

07:00—08:00
Breakfast

Ivers/Hearst/Kearns & Mountain View
08:00—11:00
Emerging Target Classes I . Session Sponsored in part by Cell Signaling Technology.
Meeting has ended...abstracts no longer viewable online.

Summit A-B
* Brian W. Metcalf, Global Blood Therapeutics, USA

Joshua Boger, Vertex Pharmaceuticals Incorporated, USA
Human Protein Kinases: A Chemogenomics Approach

Kenneth W. Wood, Cytokinetics Inc., USA
Mitotic Kinesin-Targeted Anti-Tumor Agents

Timothy M. Willson, GlaxoSmithKline, USA
Chemical and Structural Genomics of Orphan Nuclear Receptors

Nicholas K. Tonks, Cold Spring Harbor Laboratory, USA
The Protein Tyrosine Biosphases as a Platform for Development of Novel Therapeutics

09:20—09:40
Coffee Break

Summit Hallway
11:00—13:00
Poster Setup

Summit C
13:00—19:30
Poster Session 3 Open Viewing

Summit C
16:15—16:30
Coffee & Snacks Available

Summit Hallway
16:30—18:30
Emerging Target Classes II
Meeting has ended...abstracts no longer viewable online.

Summit Hallway
* Leslie J. Browne, Senesco Technologies, Inc., USA

Thomas A. Steitz, Howard Hughes Medical Institute, Yale University, USA
The Structures of Complexes Between the H. Marismortui Large Ribosomal Subunit and Nine Antibiotics

Paul G. Polakis, Genentech, Inc., USA
Development of Antibodies for Cancer Therapy

Susan M. Molineaux, Calithera Biosciences, USA
Short Talk: Targeting Mast Cells and Allergic Diseases with Novel Small Molecular Inhibitors

Kurt Jarnagin, Anacor Pharmaceuticals, Inc., USA
Short Talk: Chemogenomics

18:30—19:30
Social Hour

Summit C
18:30—19:30
Poster Session 3: Emerging Target Families

Summit C

SATURDAY, JANUARY 11

07:00—08:00
Breakfast

Ivers/Hearst/Kearns & Mountain View
08:00—11:00
New Drug Candidates I
Meeting has ended...abstracts no longer viewable online.

Summit A-B
* Paul A. Bartlett, University of California, Berkeley, USA

Nigel Walker, Amgen Inc., USA
IKK Inhibitors

David M. Goldstein, , USA
Structure Guided Design as an Approach to the Discovery of Novel p38 Inhibitors

Peter Traxler, Novartis Pharma AG, Switzerland
Tyrosine Kinase Inhibitors: From Research to Clinics

Michael K. Trower, GlaxoSmithKline, UK
Targeting Cathepsin K as a Means to Inhibit Osteoclast Mediated Bone Resorption

09:20—09:40
Coffee Break

Summit Hallway
16:15—16:30
Coffee & Snacks Available

Summit Hallway
16:30—17:45
New Drug Candidates II
Meeting has ended...abstracts no longer viewable online.

Summit A-B
* Robert F.G. Booth, Celera, USA

Steven D. Young, Merck Research Laboratories, USA
HIV Integrase Inhibitors

Lee E. Babiss, PPD, Inc., USA
Impact of Toxicogenomics on Drug Discovery and Development

17:45—18:45
Concluding Address
Meeting has ended...abstracts no longer viewable online.

Summit A-B
* Robert F.G. Booth, Celera, USA

George M. Whitesides, Harvard University, USA

18:45—19:45
Social Hour

Summit C
19:45—23:00
Entertainment

Summit C

SUNDAY, JANUARY 12

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1 R13 CA098965-01




We gratefully acknowledge additional support for this conference from:


Cell Signaling Technology, Inc.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676